Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Cediranib (AZD2171): Beyond the Viability Readout
2026-09-19
Cediranib (AZD2171) is a potent VEGFR-pathway probe for studying angiogenesis, signaling, and tumor biology. This guide shows how to interpret pathway suppression, growth inhibition, and cell death as distinct but connected experimental outcomes.
-
Azithromycin Workflows for Infection Research
2026-09-19
Build more reproducible infection, resistance, and impurity-control experiments with Azithromycin, a macrolide antibiotic that connects ribosomal mechanism to practical assay design. This guide combines culture screening, quantitative TLC, host-cell readouts, and carefully bounded animal-model translation.
-
Shh–Fgf Signaling in Guinea Pig Penile Development
2026-09-18
Wang and Zheng used comparative developmental analysis to explain why guinea pigs form a fully open urethral groove whereas mice form the penile urethra primarily by urethral plate canalization. Their expression mapping and ex vivo perturbation experiments identify differential Shh, Fgf10, and Fgfr2 activity as a major mechanistic factor linking urethral groove formation with the timing of preputial development.
-
ABT-737: BCL-2 Protein Inhibitor Workflows
2026-09-17
ABT-737 provides a practical way to test mitochondrial apoptosis dependence across lymphoma, multiple myeloma, small-cell lung cancer, and AML models. This workflow connects concentration–response experiments with endogenous BAX/BAK imaging, helping distinguish genuine pathway activation from assay or overexpression artifacts.
-
ABT-263 (Navitoclax) Apoptosis Workflows
2026-09-17
ABT-263 (Navitoclax) converts Bcl-2 family dependence into a practical experimental variable for apoptosis, senescence, and cancer biology studies. This guide shows how to pair dose-response testing with real-time imaging, mitochondrial priming, and caspase readouts to distinguish true senolytic sensitivity from nonspecific toxicity.
-
ABT-263 (Navitoclax) Apoptosis Workflow
2026-09-16
ABT-263 (Navitoclax) converts Bcl-2 family dependence into a measurable experimental variable for apoptosis, mitochondrial priming, and cancer biology studies. This guide connects dose-response design with orthogonal cell-death readouts and the emerging insight that Pol II degradation can activate death independently of transcriptional loss.
-
2'-O-Methyladenosine: From Metabolite to Mechanism
2026-09-16
A translational framework for using 2'-O-Methyladenosine to connect RNA modification biology, purine metabolism studies, quantitative mass spectrometry, and decision-ready cell-based research.
-
Nanoparticle Uptake by Human Corneal Cells
2026-09-15
Azadi and David systematically examined how PLGA nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells in a mucosa-aware in vitro model. Their results identify energy-dependent endocytosis, especially macropinocytosis and caveolae-mediated uptake, as the dominant mechanisms and provide practical design considerations for topical ocular nanomedicines.
-
mRNA-Loaded Dendritic Cells in Resected Melanoma
2026-09-15
The reference study evaluated a post-resection strategy using autologous dendritic cells loaded by electroporation with multiple melanoma-antigen mRNAs, alongside scheduled interferon alfa-2b. In 30 patients followed for more than six years, the approach showed manageable treatment-related toxicity and encouraging descriptive overall-survival rates, while its nonrandomized design limits causal interpretation.
-
Navitoclax Enhances mTOR Inhibition in PIK3CA CRC
2026-09-14
DeStefanis and colleagues identify Navitoclax as a combination partner that enhances PI3K/mTOR-pathway inhibition in PIK3CA-mutant colorectal cancer models. Their organoid screening, in vivo validation, and patient-derived organoid analyses implicate apoptosis induction, BCL-xL dependence, and KRAS-associated resistance as important determinants of response.
-
Anlotinib Hydrochloride: Designing Better Assays
2026-09-14
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose value extends beyond target potency. This article presents an assay-design framework that connects receptor phosphorylation, ERK signaling, endothelial migration, tube formation, and translational pharmacology.
-
Tricine-SDS-PAGE Electrophoresis System Guide
2026-09-13
The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is designed to improve separation of small proteins and peptides that are difficult to resolve with conventional Tris-SDS-PAGE. It is intended for research protein electrophoresis, including denaturing and non-denaturing workflows, and must not be used for diagnostic, clinical, or medical testing.
-
ABT-263 (Navitoclax): Apoptosis Research Guide
2026-09-12
ABT-263, also called Navitoclax, is an orally bioavailable Bcl-2 family inhibitor for mechanistic cancer biology and apoptosis assay workflows. Its strongest research value is the high-affinity disruption of Bcl-2, Bcl-xL, and Bcl-w interactions, with interpretation limited by context-dependent dependence on MCL1 and mitochondrial priming.
-
2-Hydroxypropyl-β-cyclodextrin Workflow Guide
2026-09-12
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide for improving the apparent aqueous solubility of poorly soluble hydrophobic compounds, particularly molecules with aromatic or phenyl groups. It is suitable for pharmaceutical solubility improvement, drug formulation excipient screening, and biochemical formulation workflows, but the available dossier does not establish therapeutic efficacy, safety, pharmacokinetic benefit, or bioavailability.
-
Perphenazine: D2 Antagonist Research Guide
2026-09-11
Perphenazine is a dopamine D2 receptor antagonist with a broader phenothiazine receptor binding profile. Research data support its use as a benchmark compound for receptor pharmacology, mitochondria-mediated cell death induction, opioid tolerance suppression, and emerging host-directed antibacterial studies.